Efficacy
A summary of the evidence supporting the effect of this protocol is below.
A total of 241 patients between September 2005 and August 2010 were randomised into 4 arms: A (3 weekly docetaxel/gemcitabine), B (3 weekly paclitaxel/gemcitabine), C (weekly docetaxel/gemcitabine) and D (weekly paclitaxel and gemcitabine). Time to progression was similar in all 4 arms.r
Time-to-progression by treatment arm (gemcitabine+docetaxel vs gemcitabine+paclitaxel)r
© BMC Cancer 2013
Efficacy data from retrospective study of weekly gemcitabine/paclitaxel in metastatic breast cancerr
Efficacyr (n=50) |
Result |
Median overall survival |
19 months |
Median progression-free survival |
7.4 months |
Complete response |
4% |
Partial response |
52% |
Stable disease |
24% |